945526-43-2
基本信息
STEM-CELL FACTOR/C-KIT 抑制剂
ISCK 03
ISCK-03
C-KIT INHIBITOR II
Stem-Cell Factor/c-Kit Inhibitor
SteM-Cell Factor/c-Kit Inhibitor, ISCK03
[4-t-Butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide
4-tert-butyl-N-(4-imidazol-1-ylphenyl)benzenesulfonamide
Benzenesulfonamide,4-(1,1-dimethylethyl)-N-[4-(1H-imidazol-1-yl)phenyl]
Stem-Cell Factor/c-Kit Inhibitor, ISCK03 - CAS 945526-43-2 - Calbiochem
[4-t-Butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide, Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[4-(1H-imidazol-1-yl)phenyl]-
物理化学性质
| 储存条件 | Sealed in dry,2-8°C |
| 溶解度 | 溶于乙醇或DMSO |
| 形态 | 固体 |
| 颜色 | 黄色 |
| 敏感性 | 感光 |
| InChIKey | XQABBHBFHWHMKF-UHFFFAOYSA-N |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H315-H319-H335 |
| 防范说明 | P261-P280a-P304+P340-P305+P351+P338-P405-P501a |
| 危险品标志 | Xi |
| 危险类别码 | 36 |
| 安全说明 | 26 |
| WGK Germany | 1 |
STEM-CELL FACTOR/C-KIT 抑制剂 价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-101443 | STEM-CELL FACTOR/C-KIT 抑制剂 ISCK03 | 945526-43-2 | 5mg | 600元 |
| 2025/02/08 | HY-101443 | STEM-CELL FACTOR/C-KIT 抑制剂 ISCK03 | 945526-43-2 | 10mM * 1mLin DMSO | 660元 |
| 2025/02/08 | HY-101443 | STEM-CELL FACTOR/C-KIT 抑制剂 ISCK03 | 945526-43-2 | 10mg | 1000元 |
常见问题列表
| Target | Value |
|
SCF
() | |
|
c-Kit
() |
Pretreatment of 501mel cells with ISCK03 inhibits SCF-induced c-kit phosphorylation dose dependently. ISCK03 also inhibits p44/42 ERK mitogen-activated protein kinase (MAPK) phosphorylation, which is known to be involved in SCF/c-kit downstream signaling. However ISCK03 does not inhibit hepatocyte growth factor (HGF)-induced phosphorylation of p44/42 ERK proteins. ISCK03, a tyrosine kinase inhibitor specific to KIT, prevents survival of CCDC26-KD cells under low-serum conditions. All treated cells exhibits sensitivity to ISCK03 in a dose-dependent manner. After ISCK03 treatment, the survival of KD cells is suppressed to the same level as that of non-KD cells. Conversely, ISCK03 treatment has limited effects on the growth of control K562 and KD clone 3–4 cells under high-serum concentration conditions.
Oral administration of ISCK03 induces the dose-dependent depigmentation of newly regrown hair, and this is reversed with cessation of ISCK03 treatment. The topical application of ISCK03 promotes the depigmentation of UV-induced hyperpigmented spots. Fontana-Masson staining analysis shows epidermal melanin is diminished in spots treated with ISCK03.